Current status of hormonal therapy of fibrocystic breast disease.
D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D002909:Chronobiology Phenomena; D003613:Danazol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005348:Fibrocystic Breast Disease / Q000188:drug therapy*; D006801:Humans; D008234:Lynestrenol / Q000009:adverse effects / Q000627:therapeutic use*; D011245:Pregnadienes / Q000627:therapeutic use*; D011388:Prolactin / Q000097:blood; D013469:Sulpiride; D013629:Tamoxifen / Q000627:therapeutic use*; D013817:Thermography; D013972:Thyrotropin / Q000097:blood*; D013973:Thyrotropin-Releasing Hormone; D013997:Time Factors
D011245:Pregnadienes; D013629:Tamoxifen; D001971:Bromocriptine; D013973:Thyrotropin-Releasing Hormone; D013469:Sulpiride; D011388:Prolactin; D013972:Thyrotropin; D003613:Danazol; D008234:Lynestrenol